BIBLIOGRAFÍA 1538. Abbot KC, Hishieh P, Cruess D, Agodoa LY, Welch PG, Taylor AJ y cols. Hospitalized valvular heart disease in patients in renal transplant waiting list: incidence, clinical correlates and outcomes. Clin Nephrol 59:79-87, 2003. 1539. Le A, Wilson R, Douek K, Pulliam L, Tolzman D, Norman D y cols. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis 24:65-71,1994. 1540. Lewis MS, Wilson RA, Walker KW, Wilson DJ, Norman DJ, Barry JM y cols. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol 89:847-850, 2002. 1541. De Lima JJ, Sabbaga E, Vieira ML, de Paula FJ, Ianhez LE, Krieger EM y cols. Coronary angiography is the best predictor of events in renal transplant candidates compared with non-invasive testing. Hypertension 42:263-8, 2003. 1542. Koch MGF, Gradaus F, Schoebel FC, Leschke M, Grabensee B. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 12:1187-91, 1997. 1543. Fredericks S, Chang R, Gregson H, Bewick M, Collinson PO, Gaze D y cols. Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta 310:199-203, 2001 1544. Goldsmith DJA and Covic A. Coronary artery disease in uremia: etiology, diagnosis and therapy. Kidney Int 60: 2059-78, 2001. 1545. Logar CM, Herzog CA and Beddhu S. Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. Am J Med Sci 325: 214-27, 2003. 1546. Roppolo LP, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A. A comparison of troponin T and troponin I as predictors of acardiac events in aptients undergoing chronic dialysis at a Veteran´s Hospital: a pilot study. J Am Coll Cardiol 34: 448- 54, 1999. 1547. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP y cols. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 334 (15): 1117-24, 2001. 1548. Haller C. Percutaneous coronary interventions in patients with renal failure: overcoming in-stent restenosis? Nephrol Dial Transplant 17: 401-3, 2002. 1549. Herzog CA, Ma JZ and Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation 109: 2866-71, 2004. 1550. Kasiske BL, Chakkera HA, Louis TA and Ma JZ. A meta-analysis of inmunosupresión withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-7, 2000. 1551. Australian New Zealand Dialysis, Transplant registry (ANZ- DATA). ANZATA Report. January 2002. 1552. Mange KC, Cizman B, Joffe M and Feldman HI. Arterial hypertension and renal allograft survival. JAMA 283: 633-8, 2000. 1553. Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B y cols. Hypertension after kidney transplantation. Am J Kidney Dis 43: 1071-81, 2004. 1554. Opelz G, Wujciak T, Ritz E for the Collaborative Transplant Study: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 53: 217-222, 1998. 1555. K/DOQUI.Guideline1: goals of antihypertensive therapy in CKD. Am J Kid Dis 43: S65-S73, 2004. 1556. Zayas CF, Guasch A. Early glomerular dysfunction in human renal allografts. Kidney Int 60:1938-1947,2001. 1557. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 85:134-138,1988. 1558. Branten AJW, Hilbrands LB, Van Hamersvelt HW, Koene RAP and Huysmans FTM. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant 13: 423-6, 1998. 1559. Midtvedt K, Hartmann A, Holdaas H and Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. Clin Transplant 15: 426-31, 2001. 1560. Srinivas TR, Meier-Kriesche HU, Kaplan B, Bennet WM. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine compared with lisinopril. Transplantation 15:1787- 92,2001. 1561. Venkat Raman G, Feehally J, Coates RA, Elliott HL, Griffin PJ, Olubodun JO y cols. Renal effects of amlodipine in normotensive renal transplant recipients. Nephrol Dial Transplant 14: 384 -8, 1999. 1562. Rump LC, Oberhauser V, Schwertfeger E, Speidel L, Zimmerhackl L, Kirste G, y cols. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. J Hypertens 18: 1115-9, 2000. 1563. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B y cols. Amlodipine reduces cyclosporine-induced hyperuricemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 18: 2147-53, 2003. 1564. Iñigo P, Campistol JM, Lario S, Piera C, Campos B, Bescos M, y cols. Effects of losartan and amlodipine on intrarrenal hemodynamics and TGF-_1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 12: 822-7, 2001. 1565. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril and doxazosin. Kidney Int 54: 130-4, 1998. 1566. Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporinetreated renal allograft recipients. Hypertension 26: 436-44, 1995. 1567. Asberg A, Midtvedt K, Vassbotn T and Hartmann A. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. Nephrol Dial Transplant 16: 1465-70, 2001. 1568. Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH y cols. Long-term follow-up of ACE-inhibitor verusus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 16: 313-20, 2003. 1569. Stigart CE, Cohen J, Vivero M, Zoltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation : An analysis of safety and efficacy. Am J Kidney Dis 35:58- 63,2000. 1570. Holgado R, Anaya F and Del Castillo D. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 16 (Suppl 1): 117-20, 2001. 234
BIBLIOGRAFÍA 1571. Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartan cilexil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 76: 1170-4, 2003. 1572. Rengel M, Gomez Da Silva, Inchaustegui L, Lampreave JL, Robledo R, Echenagusia A y cols. Renal artery stenosis after kidney transplantation: diagnostic and therapeutical approach. Kidney Int 68:S99-S106,1998. 1573. Buturovic-Ponikvar J. Renal transplant artery stenosis. Nephrol Dial Transplant 18 (Suppl 5): 74-7, 2003. 1574. Fervenza FC, Lafayette RA, Alfrey EJ and Peterson J. Renal artery stenosis in kidney transplant. Am J Kid Dis 31: 142-8, 1998. 1575. Wong W, Fynn SP, Higgins RM, Walters H, Evans S, Deane C y cols. Transplant renal artery stenosis in 77 patients-does it have an immunological cause? Transplantation 1996; 61: 215-9, 1996. 1576. K/DOQUI. Guideline 4: evaluation for renal artery disease. Am J Kidney Dis 43: S101-S106, 2004. 1577. Sacks D, Rundback JH and Martin L. Renal angioplasty/stent placement and hypertension in the year 2000. J Vasc Interv Radiol 11 (8): 949-53, 2000. 1578. Montagnino G, Tarantino A, Maccario M, Elli A, Cesana B, Ponticelli C. Long-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factors. Am J Kid Dis 35: 1135-43, 2000. 1579. Touchard G, Hauet T, Cogny Van Weydevelt, Hurault de Ligny B, Peyronnet P, Lebranchu Y y cols. Maintenance cyclosporine monotherapy after renal transplantation-clinical predictors of long-term outcome. Nephrol Dial Transplant 12: 1956-60, 1997. 1580. Hricik DE, Whalen CC, Lautman J, Bartucci MR, Moir EJ, Mayes JT y cols. Withdrawal of steroids after renal transplantation. Clinical predictors of outcome. Transplantation 53: 41-5, 1992. 1581. Gotti E, Perico N, Perna A, Gaspari F, Cattaneo D, Caruso R y cols. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 14: 755-66, 2003. 1582. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr y cols. Systemic and renal hemodynamic differences between FK 506 and cyclosporin in liver transplant recipients. Transplantation 55: 1332-9, 1993. 1583. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP y cols. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809-17, 2004. 235
- Page 1 and 2:
NEFROLOGIA VOLUMEN 24. Suplemento N
- Page 3 and 4:
NEFROLOGÍA. VOLUMEN 24. Suplemento
- Page 5 and 6:
Guías SEN RIÑÓN Y ENFERMEDAD CAR
- Page 7 and 8:
ÍNDICE DE TABLAS Tabla 20. Tabla 2
- Page 9 and 10:
ÍNDICE DE TABLAS Tabla 63. Tabla 6
- Page 11 and 12:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 13 and 14:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 15 and 16:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 17 and 18:
RIÑÓN Y ENFERMEDAD CARDIOVASCULAR
- Page 19 and 20:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 21 and 22:
ENFERMEDAD RENAL Y PATOLOGÍA CARDI
- Page 23 and 24:
ENFERMEDAD RENAL Y PATOLOGÍA CARDI
- Page 25 and 26:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 27 and 28:
DEFINICIÓNES EN ENFERMEDAD RENAL C
- Page 29 and 30:
DEFINICIÓNES EN ENFERMEDAD RENAL C
- Page 31 and 32:
DEFINICIÓNES EN ENFERMEDAD RENAL C
- Page 33 and 34:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 35 and 36:
EVALUACIÓN DE LA FUNCIÓN RENAL ME
- Page 37 and 38:
EVALUACIÓN DE LA FUNCIÓN RENAL ci
- Page 39 and 40:
EVALUACIÓN DE LA FUNCIÓN RENAL se
- Page 41 and 42:
EVALUACIÓN DE LA FUNCIÓN RENAL Un
- Page 43 and 44:
EVALUACIÓN DE LA FUNCIÓN RENAL De
- Page 45 and 46:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 47 and 48:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 49 and 50:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 51 and 52:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 53 and 54:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 55 and 56:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 57 and 58:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 59 and 60:
LA ENFERMEDAD RENAL COMO NUEVO FACT
- Page 61 and 62:
OTROS FACTORES DE RIESGO CARDIOVASC
- Page 63 and 64:
OTROS FACTORES DE RIESGO CARDIOVASC
- Page 65 and 66:
OTROS FACTORES DE RIESGO CARDIOVASC
- Page 67 and 68:
OTROS FACTORES DE RIESGO CARDIOVASC
- Page 69 and 70:
OTROS FACTORES DE RIESGO CARDIOVASC
- Page 71 and 72:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 73 and 74:
NEFROPATÍA VASCULAR CONCEPTOS La n
- Page 75 and 76:
NEFROPATÍA VASCULAR Tabla 38. Prin
- Page 77 and 78:
NEFROPATÍA VASCULAR Nefropatía is
- Page 79 and 80:
NEFROPATÍA VASCULAR Sí Arteriogra
- Page 81 and 82:
NEFROPATÍA VASCULAR 1 Supervivenci
- Page 83 and 84:
ENFERMEDAD RENAL CRÓNICA Població
- Page 85 and 86:
ENFERMEDAD RENAL CRÓNICA La segund
- Page 87 and 88:
ENFERMEDAD RENAL CRÓNICA TRS Fig.
- Page 89 and 90:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 91 and 92:
TRATAMIENTO DE LA HTA EN ENFERMOS C
- Page 93 and 94:
TRATAMIENTO DE LA HTA EN ENFERMOS C
- Page 95 and 96:
TRATAMIENTO DE LA HTA EN ENFERMOS C
- Page 97 and 98:
TRATAMIENTO DE LA HTA EN ENFERMOS C
- Page 99 and 100:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 101 and 102:
BLOQUEO DEL SISTEMA RENINA-ANGIOTEN
- Page 103 and 104:
BLOQUEO DEL SISTEMA RENINA-ANGIOTEN
- Page 105 and 106:
BLOQUEO DEL SISTEMA RENINA-ANGIOTEN
- Page 107 and 108:
BLOQUEO DEL SISTEMA RENINA-ANGIOTEN
- Page 109 and 110:
BLOQUEO DEL SISTEMA RENINA-ANGIOTEN
- Page 111 and 112:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 113 and 114:
TERAPÉUTICA HIPOLEMIANTE EN PACIEN
- Page 115 and 116:
TERAPÉUTICA HIPOLEMIANTE EN PACIEN
- Page 117 and 118:
TERAPÉUTICA HIPOLEMIANTE EN PACIEN
- Page 119 and 120:
TERAPÉUTICA HIPOLEMIANTE EN PACIEN
- Page 121 and 122:
TERAPÉUTICA HIPOLEMIANTE EN PACIEN
- Page 123 and 124:
TERAPÉUTICA HIPOLEMIANTE EN PACIEN
- Page 125 and 126:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 127 and 128:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 129 and 130:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 131 and 132:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 133 and 134:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 135 and 136:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 137 and 138:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 139 and 140:
TERAPÉUTICA ANTIAGREGANTE PLAQUETA
- Page 141 and 142:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 143 and 144:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 145 and 146:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 147 and 148:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 149 and 150:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 151 and 152:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 153 and 154:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 155 and 156:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 157 and 158:
ENFERMEDAD CARDIOVASCULAR Y ENFERME
- Page 159 and 160:
NEFROLOGÍA. Volumen 24. Suplemento
- Page 161 and 162:
PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 163 and 164:
PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 165 and 166:
PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 167 and 168:
PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 169 and 170:
PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 171 and 172:
ENFERMEDAD CARDIOVASCULAR EN PACIEN
- Page 173 and 174:
ENFERMEDAD CARDIOVASCULAR EN PACIEN
- Page 175 and 176:
ENFERMEDAD CARDIOVASCULAR EN PACIEN
- Page 177 and 178:
ENFERMEDAD CARDIOVASCULAR EN PACIEN
- Page 179 and 180:
PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 181 and 182: PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 183 and 184: PECULIARIDADES DEL TRATAMIENTO ANTI
- Page 185 and 186: NEFROLOGÍA. Volumen 24. Suplemento
- Page 187 and 188: BIBLIOGRAFÍA 68. Harvey JM, Howie
- Page 189 and 190: BIBLIOGRAFÍA for the African-ameri
- Page 191 and 192: BIBLIOGRAFÍA 208. Culleton BF, Lar
- Page 193 and 194: BIBLIOGRAFÍA Multinational Study o
- Page 195 and 196: BIBLIOGRAFÍA 327. Zoccali C, Bened
- Page 197 and 198: BIBLIOGRAFÍA 392. Kenchaiah S, Eva
- Page 199 and 200: BIBLIOGRAFÍA 460. Kimura H, Gejyo
- Page 201 and 202: BIBLIOGRAFÍA 521. Bologa RM, Levin
- Page 203 and 204: BIBLIOGRAFÍA 586. López G, Ruiz J
- Page 205 and 206: BIBLIOGRAFÍA 648. Estacio RO, Jeff
- Page 207 and 208: BIBLIOGRAFÍA 706. Harnett JD, Fole
- Page 209 and 210: BIBLIOGRAFÍA 772. Quaschning T, Sc
- Page 211 and 212: BIBLIOGRAFÍA Diabetes Complication
- Page 213 and 214: BIBLIOGRAFÍA 903. Simpson RJ Jr. P
- Page 215 and 216: BIBLIOGRAFÍA 965. Shek A, Ferrill
- Page 217 and 218: BIBLIOGRAFÍA 1033. Scarborough RM:
- Page 219 and 220: BIBLIOGRAFÍA European Society of C
- Page 221 and 222: BIBLIOGRAFÍA 1167. Rostand SG, Gre
- Page 223 and 224: BIBLIOGRAFÍA 1233. Chertow GM, Nor
- Page 225 and 226: BIBLIOGRAFÍA 1299. Webb AT, Franks
- Page 227 and 228: BIBLIOGRAFÍA 1368. Zucchelli P, Sa
- Page 229 and 230: BIBLIOGRAFÍA 1438. Kohse KP, Feife
- Page 231: BIBLIOGRAFÍA 1507. Saunders RN, Me